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Retinoic acid (RA) induces differentiation of neuro-
blastoma cells in vitro and is used with variable
success to treat aggressive forms of this disease.
This variability in clinical response to RA is enigmatic,
as no mutations in components of the RA signaling
cascade have been found. Using a large-scale RNAi
genetic screen, we identify crosstalk between the
tumor suppressor NF1 and retinoic acid-induced
differentiation in neuroblastoma. Loss of NF1 acti-
vates RAS-MEK signaling, which in turn represses
ZNF423, a critical transcriptional coactivator of the
retinoic acid receptors. Neuroblastomas with low
levels of both NF1 and ZNF423 have extremely
poor outcome. We find NF1 mutations in neuroblas-
toma cell lines and in primary tumors. Inhibition of
MEK signaling downstream of NF1 restores respon-
siveness to RA, suggesting a therapeutic strategy
to overcome RA resistance in NF1-deficient neuro-
blastomas.INTRODUCTION
Neuroblastoma is a malignancy of early childhood that arises
from the developing autonomic nervous system (Maris et al.,
2007). It is the most frequently diagnosed cancer in the first
year of life and shows a remarkably heterogeneous clinical
behavior. Some tumors regress spontaneously, whereas others
progress to highly aggressive metastatic disease with a poor
overall survival rate. Amplification of the MYCN oncogene and/
or loss of the chromosomal regions 1p36 and 11q23 correlate
with poor disease outcome (Attiyeh et al., 2005; Caron et al.,218 Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc.1996; Seeger et al., 1985). Recurrent gene mutations are rela-
tively rare in neuroblastoma. Somatic and germline activating
mutations in the ALK kinase have been identified in 7% of
neuroblastomas, providing the basis for a promising molecular
targeted therapy in this subgroup (reviewed in Mosse et al.,
2009). PHOX2B and PTPN11 mutations were found in 2% and
3% of neuroblastomas, respectively (Bentires-Alj et al., 2004;
van Limpt et al., 2004).
Neuroblastomas frequently transdifferentiate intomore benign
ganglioneuroblastomas and ganglioneuromas. Progression in
the opposite direction is also observed in patients. The vitamin
A metabolite retinoic acid (RA) is an important morphogen for
the developing nervous system in vivo and capable of differenti-
ating neuronal cells in vitro (Duester, 2008). Various neuroblas-
toma cell lines cease proliferation, differentiate into neuronal-
like cells, or undergo apoptosis upon exposure to RA (Sidell
et al., 1983). These observations established the basis for the
clinical application of RA in the treatment of neuroblastoma.
RA is one of the few targeted therapeutics currently used in the
clinic for aggressive neuroblastoma, but the benefit is limited.
A phase III randomized trial showed that treatment with 13-cis-
RA given after completion of intensive chemoradiotherapy yields
a slight but significant improvement in event-free survival in
high-risk neuroblastoma (Matthay et al., 1999, 2009).
The physiological functions of retinoids are primarily exerted
through the regulation of specific target genes mediated by
retinoid acid receptors (RARs). RARs are nuclear hormone
receptors that function as ligand-dependent transcription
factors (reviewed in Rochette-Egly and Germain, 2009). Their
activity requires heterodimerization with the retinoid X receptors
(RXRs) that can also associate with several other nuclear
hormone receptors. RAR/RXR heterodimers constitutively bind
to retinoic acid response elements (RAREs) in the promoter
regions of target genes and actively repress transcription in the
absence of ligand. This process involves recruitment of the
corepressors NCoR and SMRT and histone deacetylases
(HDACs). RA binds to RAR and triggers conformational changes
that release the corepressors and in turn promote the assembly
of coactivator complexes. Subsequently, transcription of target
genes is initiated. Many of the coactivators, including CBP/
p300, PCAF, and SRC1–3 (NCOA1–3), possess histone acety-
lase (HAT) activity that promotes transactivation of RAR/RXR.
In contrast, ligand-dependent corepressors such as LCoR and
PRAME recruit HDACs or PcG proteins to ligand-bound RAR/
RXR complexes to repress their activities (Epping et al., 2005;
Fernandes et al., 2003). Therefore, co-activators/repressors
play crucial roles for the context-dependent action of RA and
may be important determinants and biomarkers for RA-based
therapies in the clinic.
Recently, we have used a large-scale RNA interference (RNAi)
based screen in F9 mouse teratocarcinoma cells, a widely used
model system to study RA signaling (Huang et al., 2009), to
identify ZNF423 as a critical cofactor required for RAR/RXR
function. We found that ZNF423 is also crucial for RA-mediated
growth arrest and differentiation in human neuroblastoma
cell lines and that its reduced expression was a powerful marker
of poor prognosis in neuroblastoma patients, independent of
MYCN amplification. However, we have not observed loss of
heterozygosity at the ZNF423 locus in primary neuroblastomas,
nor could we restore ZNF423 levels in neuroblastoma cell lines
with low ZNF423 by DNA-demethylating agents. These results
indicate thatZNF423 expression is determined by transcriptional
regulation, rather than by epigenetic silencing or genetic loss.
The signaling pathways that regulate ZNF423 expression could
therefore be the critical components governing the RA response.
As pointed out above, the overall response rate to RA in neuro-
blastoma patients is low, suggesting that only a subgroup of
patients benefits from the treatment. Currently, no predictive
markers of RA responsiveness are available for clinical use. No
alterations in any of the core components of the RA signaling
pathway have been described in neuroblastoma tumors, posing
a conundrum of how to explain the diversity in RA sensitivity. To
gain more mechanistic insights into the factors that control RA
responsiveness in neuroblastoma, we performed an unbiased
large-scale RNAi screen in neuroblastoma cells. We identify
here the tumor suppressor NF1 as a major determinant of RA
sensitivity in neuroblastoma cells and find genetic alterations in
NF1 in primary tumors and neuroblastoma cell lines. We provide
proof-of-concept experiments for a therapeutic strategy to
overcome RA resistance in NF1-deficient neuroblastomas by
the coapplication of RA with MEK inhibitors.
RESULTS
NF1 Suppression Confers Resistance to RA
in Neuroblastoma
In response to RA, the human neuroblastoma cell line SH-SY5Y
ceases proliferation and differentiates into neuronal-like cells.
To identify novel determinants of RA resistance in neuroblas-
toma, we performed a large-scale RNAi-based loss-of-function
genetic screen using a collection of 24,000 short-hairpin (shRNA)
vectors targeting 8000 human genes (Berns et al., 2004). We
used a barcoding technology to identify genes whose suppres-sion causes resistance to RA (Brummelkamp et al., 2006). The
entire shRNA library was introduced into SH-SY5Y cells by retro-
viral infection and cells were plated at low density with or without
RA (Figure 1A). After 4 weeks of RA selection, genomic DNA was
isolated from both cultures. The stably integrated shRNA
cassettes (19-mer barcode sequences) were recovered by
PCR. The relative abundance of individual shRNA vectors was
quantified by hybridization of the PCR products to microarrays
harboring all 24,000 barcode sequences. The barcode screen
was carried out in triplicate and the results are shown in
Figure 1B. Each dot in the M/A plot represents one individual
shRNA vector in the library. M and A values reflect relative
enrichment and hybridization signal intensity. Reproducible
outliers are generally located in the right upper corner. Low-
intensity spots are prone to technical artifacts and thus unreli-
able. Thereforewe restricted our candidate selection by applying
M/A cut-off values as indicated in Figure 1B. To rule out ‘‘off-
target’’ effects, we only consider a gene identified from the
screen as a genuine hit if at least two independent shRNAs
suppress the expression of the target and also confer RA resis-
tance. Within the list of 44 candidate hits fulfilling the cut-off
criteria, the only gene that was represented by two shRNAs
was the tumor suppressor gene NF1 (neurofibromin 1), and it
was thus studied further.
To validate the results of the screen, we individually introduced
into SH-SY5Y cells the two NF1 shRNAs (#1 and #2) from the
library and one newly generated (#3). Vectors targeting GFP
(shGFP) or harboring only the empty vector (pRS) served as
controls throughout the study. All three NF1 knockdown vectors
conferred resistance to RA in long-term colony formation assays
and efficiently suppressed NF1 mRNA and protein expression
(Figure 1C). We also noted a growth advantage of NF1 knock-
down cells in the absence of exogenously added RA. This may
result from resistance to low levels of RA present in the culture
medium or from an RA-independent proliferation advantage.
Therefore, we used the 3T3 protocol to perform a long-term
proliferation assay of SH-SY5Y cells expressing shRNAs against
NF1,GFP, or control vector (pRS) (Figure 1D). A slightly increased
growth rate of NF1 knockdown cells was indeed detected in the
absence of exogenous RA. However, when exposed to RA,
shNF1-expressing cells continued to proliferate, whereas control
cells completely ceased proliferation after a latency of about
10 days and the total cell number even declined, indicating that
prolonged RA treatment caused cell death of the control cells.
Thus, NF1 knockdown cells are clearly rescued from RA-medi-
ated differentiation and growth arrest. Identical results were ob-
tained in other neuroblastoma cell lines having different levels
of MYCN amplification (SK-N-SH, SJ-NB6, Kelly, HT-230, and
LAN-5; Figure S1 available online and data not shown), indicating
thatNF1 knockdown can cause resistance to RA independent of
MYCN amplification status in a range of neuroblastomas.
RAS Signaling Linked to RA Response
It has been found that the neuroblastoma cell line SJ-NB-10
(NB90-9) harbors a homozygous deletion of some exons of the
NF1 gene, suggesting that these cells could be insensitive to
RA (The et al., 1993). Figure 2 shows that SJ-NB-10 cells indeed
lack NF1mRNA and protein (Figure 2A) and fail to respond to RACell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc. 219
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Figure 1. A Genome-wide RNAi Screen Identifies
NF1 as a Critical Determinant of RA Sensitivity in
Neuroblastoma Cells
(A) Schematic outline of the RA resistance barcode screen
performed in SH-SY5Y cells. Human shRNA library poly-
clonal virus was produced to infect SH-SY5Y cells, which
were then left untreated (control) or treated with 100 nM
all-trans retinoic acid (RA). After 4 weeks of selection,
shRNA inserts from both populations were recovered,
labeled, and hybridized to DNA microarrays as described
(Brummelkamp et al., 2006).
(B) Analysis of the relative abundance of the recovered
shRNA cassettes from RA barcode experiment. Averaged
data from three independent experiments were normalized
and 2log transformed. Among the 44 top shRNA candi-
dates (M > 1.5 and A > 7.5), two independent shNF1
vectors (in red) were identified.
(C) Validation of independent shRNAs targeting NF1. The
functional phenotypes of nonoverlapping shNF1 vectors
are indicated by the colony formation assay in 100 nM
RA. The pRS vector and shGFP were used as controls.
The cells were fixed, stained, and photographed after
14 days (untreated) or 21 days (RA treatment). The knock-
down ability of each of the shRNAs was measured by
examining the NF1 mRNA levels by qRT-PCR and the
NF1 protein levels by western blotting. Error bars denote
standard deviation (SD). See also Figure S1.
(D) RA resistance by NF1 RNAi was dependent on RA
signaling. Proliferation curves according to the 3T3 pro-
tocol of SH-SY5Y cells expressing shNF1 vectors, shGFP,
or pRS, in the absence and presence of RA (100 nM). Error
bars denote SD.(Figure 2B). NF1 is a large protein that has GTPase-activating
activity (GAP) and functions as a negative regulator of RAS
proteins by promoting their conversion from the active GTP-
bound to the inactive GDP-bound form (Cichowski and Jacks,
2001; Martin et al., 1990). Loss of NF1 expression results in
hyperactive RAS signaling, and therefore we reasoned that
hyperactive RAS signaling could cause RA resistance in this
NF1-deficient neuroblastoma cell line.
We stably introduced the GAP-related domain of NF1 (NF1-
GRD) into the NF1-deficient SJ-NB-10 cells. Expression of the
NF1-GRD is widely used to restore NF1-dependent GAP activity
and thus inhibition of RAS activity in cells lacking NF1 (Martin
et al., 1990). Expression of the NF1-GRD was determined by
qRT-PCR using NF1-GRD-specific primers (Figure 2D). SJ-NB-
10 cells expressing NF1-GRD were exquisitely sensitive to RA,
and cell growth was impaired by almost 7-fold relative to the
control cells. In the absence of RA, however, the inhibition was
only 2.5-fold, underscoring the RA-specific sensitization effect
(Figure 2C).
Our results suggest that hyperactive RAS signaling is respon-
sible for the RA resistance associated with a naturally occurring220 Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc.homozygous NF1 deletion in a human neuro-
blastoma cell line. To substantiate the role of
RAS signaling further, we tested if an activated
RAS (KRASV12, Figure 2F) oncogene can cause
RA resistance in sensitive SH-SY5Y cells.
Similar to NF1 knockdown, cells expressing theKRAS oncogene potently bypassed RA-induced growth arrest
(Figure 2E).
To investigate the role of endogenous KRAS in the RA resis-
tance caused by NF1 loss, we performed an epistasis analysis.
SH-SY5Y cells were simultaneously infected with shRNAs
against KRAS and NF1. Suppression of KRAS (Figure 2H) in
combination with NF1 impaired the occurrence of RA-resistant
cells driven by NF1 knockdown, whereas cells coinfected with
shNF1 and pRSwere highly resistant to RA (Figure 2G). This indi-
cates that KRAS is critically required to mediate the effects of
NF1 knockdown on the RA response.
NF1 Loss Inhibits Transcriptional Response to RA
RA exerts its biological effects largely through gene regulation.
We therefore addressed whether suppression of NF1 interferes
with the transcriptional response to RA. ShRNAs targeting
NF1 or GFP were cotransfected with a reporter gene containing
a consensus RARE linked to luciferase (RARE-Luc). Both
shRNAs against NF1 inhibited the reporter gene activation by
RA (Figure 3A). Moreover, NF1 knockdown also suppressed
expression of bona fide endogenous RA target genes RARb,
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Figure 2. RAS Signaling Linked to RA
Response in Neuroblastoma Cells
(A) NF1 deficiency in SJ-NB10 (NB90-9) cells. NF1
mRNA and protein were undetectable by
qRT-PCR and western blotting. SH-SY5Y cells
were included as a positive control. Error bars
denote SD.
(B) SJ-NB10 cells are insensitive to RA. SJ-NB10
and the control SH-SY5Y cells were grown in the
absence or presence of RA (100 nM). Treated
and untreated dishes of each cell line were fixed,
stained, and photographed at the same time.
SH-SY5Y cells were harvested after 14 days and
SJ-NB10 cells after 28 days.
(C) Enforced expression of NF1-GRD in SJ-NB10
cells leads to growth inhibition in the absence of
exogenous RA and enhanced responses to RA.
Cells expressing pQCXIP-vector, -GFP, or -NF1-
GRD were grown in the absence or presence of
RA (100 nM) for 28 days, after which cells were
fixed, stained, and photographed. Relative cell
growth was then measured by crystal violet quan-
tification. Fold inhibition values were normalized to
cells infected with pQCXIP vector. Error bars
denote SD.
(D) Relative NF1-GRD mRNA levels in SH-SY5Y
cells and SJ-NB10 cells expressing pQCXIP-
vector, -GFP, or -NF1-GRD. Error bars denote SD.
(E) Ectopic expression of KRASV12 in SH-SY5Y
cells leads to RA resistance. Cells expressing
pBABE-vector or -KRASV12 were grown in the
absence or presence of RA (100 nM). The cells
were fixed, stained, and photographed after
14 days (untreated) or 21 days (RA treatment).
(F) The RAS protein expression levels in SH-SY5Y
cells expressing pBABE-vector or -KRASV12.
(G) Endogenous KRAS is required for the RA resis-
tance driven by NF1 knockdown. SH-SY5Y cells
expressing pRS, shNF1 plus pRS, or shNF1 plus
shKRAS were grown in the absence or presence
of RA (1 mM). The cells were fixed, stained, and
photographed after 14 days (untreated) or
21 days (RA treatment). Relative cell growth was
then measured by crystal violet quantification.
Fold inhibition values were normalized to cells in-
fected with shNF1 plus pRS, in the absence or
presence of RA. Error bars denote SD.
(H) The KRAS mRNA levels in SH-SY5Y cells
expressing pRS, shNF1 plus pRS, or shNF1 plus
shKRAS. Error bars denote SD.CRABP2, and TGM2 (Figures 3B–3D). Similarly, exogenous
expression of KRASV12 also repressed RA-dependent target
gene activation. Similar results were obtained in other neuro-
blastoma cell lines (data not shown). These results further
suggest that hyperactive RAS signaling downstream of NF1
blocks the transcriptional response to RA in neuroblastoma
cells. Transcriptional induction of the RET tyrosine kinase, a
gene associated with neuroblastoma differentiation (Bunone
et al., 1995), was consistently blocked in shNF1- and
KRASV12-expressing cells, indicating that NF1 suppression
overrides not only proliferation arrest but also differentiation
induced by RA (Figure 3E).NF1 Loss Downregulates the RAR/RXR Coactivator
ZNF423
As cofactors are critical determinants of RAR/RXR transcrip-
tional activity, we asked whether modulation of a cofactor(s)
might play a role in the RA resistance caused by NF1 knock-
down. Global gene expression analysis in NF1 knockdown cells
identified 196 and 167 genes that were greater than 2-fold up- or
downregulated (Table S1). Among these genes, we found the
RAR/RXR coactivator ZNF423 to be significantly repressed in
shNF1-expressing cells. We have previously shown that
ZNF423 physically interacts with RAR/RXR heterodimers and
binds to RA-responsive promoters (Huang et al., 2009).Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc. 221
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Figure 3. NF1 Loss Inhibits Transcriptional
Response to RA
(A) NF1 RNAi inhibits activation of a RARE-lucif-
erase (RARE-Luc) reporter gene by endogenous
RAR/RXR in response to 24 hr of 100 nM RA stim-
ulation in SH-SY5Y cells. Normalized luciferase
activities shown are ratios between luciferase
values and Renilla internal control values. Error
bars denote SD.
(B–E) NF1 knockdown or ectopic expression of
KRASV12 suppresses transcriptional activation of
endogenous RA target genes in response to RA.
mRNA expression analysis of RA target genes
RARb (B), CRABP2 (C), TGM2 (D), and RET (E) in
SH-SY5Y cells expressing controls, shRNAs tar-
geting NF1, or pBABE- KRASV12 after 100 nM RA
stimulation for 7 days. Error bars denote SD.Suppression of ZNF423 caused RA resistance in multiple neuro-
blastoma cell lines, and reconstitution of ZNF423 levels in
ZNF423low neuroblastoma cell lines restored their response to
RA. Thus, repression of ZNF423 by loss of NF1 could play an
important role in mediating RA resistance. We confirmed
downregulation of ZNF423 mRNA and protein levels in shNF1-
expressing cells by qRT-PCR and western blotting (Figures 4A
and 4B). A reduction in ZNF423 expression by knockdown of
NF1was also seen in additional neuroblastoma cell lines (Figures
S2A–S2D).
To address whether suppression of ZNF423 is causal for the
RA resistance of NF1 knockdown cells, we re-expressed
ZNF423 at physiological levels in shNF1-expressing SH-SY5Y
cells (Figures 4C and 4D). Reconstitution of ZNF423was capable222 Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc.of partially restoring responsiveness to
RA in otherwise insensitive NF1 knock-
down cells (Figure 4C). In line with our
previous study, ZNF423 expression
caused hypersensitivity to RA along
with a moderate inhibition of proliferation
(Figure 4C). ZNF423 reconstitution in NF1
knockdown cells also restored expres-
sion of bona fide RA target genes, such
as TGM2 and CRABP2 (Figures 4E
and 4F). Our results demonstrate that
ZNF423 is a major, but possibly not the
only, component downstream of NF1 in
the control of RA sensitivity in neuroblas-
toma cells.
ZNF423 Predicts RA
Responsiveness
As NF1 loss causes resistance to RA, at
least in part, by suppression of ZNF423,
our data raise the possibility that
ZNF423 levels might predict sensitivity
of neuroblastomas to RA. To begin to
address this, we explored the predictive
value of ZNF423 expression for RA
responsiveness in a panel of 26 dif-ferent neuroblastoma cell lines. We investigated the sensitivity
to RA (100 nM) by long-term colony formation assays. The
response to RA was determined by the relative growth of
treated versus untreated cultures. ZNF423 mRNA levels were
measured by qRT-PCR in the absence of RA (Figure 4G and
Figures S2E and S2F). The response to RA ranged from highly
sensitive to fully resistant. High expression of ZNF423 was
significantly associated with sensitivity to RA (Spearman
correlation, p = 0.01). The range of ZNF423 expression within
the cell line panel was comparable to the regulation observed
by knockdown of NF1 in SH-SY5Y and other neuroblastoma
cell lines (Figure 4A, Figure S2E). This underscores the
functional relevance of ZNF423 suppression by knockdown
of NF1.
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Figure 4. NF1 Loss Suppresses RA
Response by Downregulating the RAR/
RXR Coactivator ZNF423
(A and B) NF1 RNAi leads to downregulation of
ZNF423 mRNA and protein levels. SH-SY5Y cells
expressing controls and shRNAs targeting NF1
were grown in the absence or presence of RA
(100 nM) for 7 days. (A) ZNF423 mRNA levels are
suppressed in NF1 knockdown cells. (B) ZNF423
protein levels are also reduced n NF1 knockdown
cells. See also Figure S2 and Table S1.
(C) Re-expression of ZNF423 reverses the RA
resistance driven by NF1 knockdown. SH-SY5Y
cells expressing MSCV control or MSCV-ZNF423
were retrovirally infected with viruses containing
pRS or shNF1 and were grown in the absence or
presence of 1 mM RA. Cells were then fixed,
stained, and photographed after 12 days
(untreated) or 14 days (RA treatment). Relative
cell growth was then measured by crystal violet
quantification. Fold inhibition values were normal-
ized to cells expressing both MSCV control and
shNF1, in the absence or presence of RA. Error
bars denote SD.
(D) The NF1 and ZNF423 protein levels in SH-SY5Y
cells described in Figure 4C. Cells were grown in
the presence of 1 mM RA for 14 days.
(E and F) Re-expression of ZNF423 restores acti-
vation of the RA target genes TGM2 and CRABP2
in NF1 knockdown cells. Error bars denote SD,
*p < 0.01 (t test for comparison of three indepen-
dent biological experiments).
(G) ZNF423 expression and RA responsiveness in
neuroblastoma cell lines. ZNF423 mRNA levels
from a panel of 26 different neuroblastoma cell
lines were determined by qRT-PCR. The relative
viability in 100 nM RA was determined by the ratio
of cell growth of treated versus untreated cultures
measured by crystal violet quantification after
long-term colony formation assays. A significant
association between ZNF423 expression and RA
sensitivity was determined by Spearman rank
correlation analysis.
See also Figure S2.NF1 Expression Predicts Outcome of Neuroblastoma
Wehave shown previously that ZNF423 expression is prognostic
for event-free survival of neuroblastoma patients (Huang et al.,
2009). Given the functional connection between NF1 and
ZNF423, we investigated a possible prognostic significance of
NF1 expression in neuroblastoma bymicroarray analysis in three
independent patient cohorts. The first cohort consists of 88
neuroblastoma patients from the Academic Medical Center
(AMC) in Amsterdam, Netherlands (Huang et al., 2009). We
used this cohort as a ‘‘training set’’ to generate an optimal cut-
off value of NF1 expression by a Kaplan scanning approach
(see Experimental Procedures for details). Patients were then
classified into NF1 low or high based on their NF1 levels in the
primary tumors using this cut-off value, and progression-free
survival was assessed by Kaplan-Meier analysis. The NF1high
subgroup had a significantly better outcome than the NF1lowsubgroup (Figure 5A). Similar results were obtained with median
expression (p = 0.028) or average expression (p = 0.017) as
cut-off values for NF1 expression. Importantly, NF1 retains
prognostic significance in combination with any of the four clin-
ically used prognostic markers: MYCN amplification, deletion of
chromosomal band 1p36 (LOH 1p36), age (<18 months), and
stage in a multivariate analysis (Table S2).
We then validated the prognostic value of NF1 expression in
an independent cohort of 102 neuroblastoma patients from the
Childrens Hospital Los Angeles (CHLA) with metastatic tumors
lacking MYCN amplification, for which progression-free survival
data are known (Asgharzadeh et al., 2006). Because the same
microarray platform was used, the NF1 expression from both
datasets was normalized and the cut-off value used in AMC
series was applied to the validation cohort. Again, high level of
NF1 expression correlated with longer progression-free survivalCell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc. 223
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Figure 5. NF1 Expression Predicts
Outcome of Neuroblastoma, and the Com-
bined Expression Status ofNF1 and ZNF423
is a Powerful Prognostic Marker
(A) Kaplan-Meier analysis of the AMC cohort
(n = 88) documenting increased progression-free
survival (PFS) of neuroblastoma patients with
tumors that have high NF1 expression (NF1 high)
versus patients with tumors that have low NF1
expression (NF1 low), using the NF1 cut-off value
determined as described in the text. See also
Table S2.
(B) Kaplan-Meier analysis of PFS for the AMC
cohort classified by the combined expression
status of NF1 and ZNF423. The NF1 cut-off value
was the same as above and ZNF423 cut-off value
was as described previously (Huang et al., 2009).
(C) Kaplan-Meier analysis of PFS for a second
independent set of 102 patients from CHLA diag-
nosed with metastatic neuroblastomas lacking
MYCN amplification (Asgharzadeh et al., 2006).
These patients were classified using the same
NF1 cut-off value determined from the AMC
cohort.
(D) Kaplan-Meier analysis of PFS for the CHLA
cohort classified by the combined expression
status of NF1 and ZNF423. The cut-off values for
NF1 and ZNF423 were the same as above.
(E and F) Kaplan-Meier analysis of PFS for the
Oberthuer cohort (Oberthuer et al., 2006; valida-
tion set, n = 126) classified by the expression
status of NF1 (E) and the combined expression
status of NF1 and ZNF423 (F). The cut-off values
for NF1 and ZNF423 were determined in the
Oberthuer training set (n = 125).and in return low NF1 expression was associated with poor
outcome (Figure 5C). When we combined the expression status
ofNF1 andZNF423, patients classified asNF1low/ZNF423low had
the poorest disease outcome, whereas the NF1high/ZNF423high
groups had the best outcome (Figures 5B and 5D). High expres-
sion of either NF1 or ZNF423 alone was correlated with an
intermediate progression-free survival. As the CHLA validation
cohort was restricted to a subset of high-risk tumors without
MYCN amplification, we analyzed a third independent dataset
that covers all stages includingMYCN-amplified tumors (Oberth-
uer et al., 2006). These gene expression data were generated on
a different microarray platform. Therefore, we randomly divided
the entire cohort into a training set (n = 125) and validation set
(n = 126), and cut-off values for NF1 and ZNF423 were deter-
mined as described above in the training set and then applied
to the validation set. Again, low expression of NF1 and ZNF423224 Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc.correlated with poor outcome (Figure 5E
and data not shown). When we combined
NF1 and ZNF423 expression, patients
classified as NF1low/ZNF423low had the
poorest disease outcome, whereas the
NF1high/ZNF423high group had the best
outcome (Figure 5F). Prognostic signifi-
cance of NF1 and the combined NF1/
ZNF423 expression status were indepen-dent ofMYCN amplification in a multivariate analysis (Table S2).
Differences in progression-free survival were consistent and
statistically significant in all three patient cohorts. Moreover,
the ZNF42low group was significantly enriched for NF1 low
tumors (Wilcoxon test, p < 0.001 in all three cohorts). This is in
line with the functional interaction between NF1 and ZNF423
that we observed in cell lines. In summary, the combined expres-
sion status of the two functionally connected genes, NF1 and
ZNF423, is a powerful prognostic marker in neuroblastoma.
NF1 Mutations in Neuroblastoma
Most of the patients with neurofibromatosis type 1 harbor muta-
tions of the NF1 gene, ranging from single point mutations to
larger deletions (Messiaen et al., 2000; Wimmer et al., 2006;
Zatkova et al., 2004). NF1 mutations and deletions were also
found in 23% of glioblastomas, a highly aggressive adulthood
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Figure 6. NF1 Mutations in Neuroblastoma
(A) NF1 protein levels in a panel of 25 neuroblas-
toma cell lines as determined by western blotting.
See also Figure S3.
(B) Schematic representation of genomic aberra-
tions in the NF1 gene in neuroblastoma cell lines.
Vertical lines in theNF1 locus correspond to exons
and horizontal arrows depict regions of hemizy-
gous or homozygous deletions. See also Fig-
ure S4.
(C) Schematic representation of genomic aberra-
tions in the NF1 gene in primary neuroblastomas.
Vertical arrows indicate the position of the identi-
fied NF1 mutations. Horizontal arrows depict
regions of hemizygous or homozygous deletion
and dashed lines indicate the regions affected by
the duplication of 17q. See also Figure S4.brain tumor (TCGA_Network, 2008). A role for NF1 in the patho-
genesis of neuroblastoma has been discussed based on cell line
observations but never studied systematically in a large cohort of
primary neuroblastomas (The et al., 1993).
In a panel of 25 neuroblastoma cell lines, we found loss of NF1
protein expression in approximately one third (Figure 6A).
Absence of NF1 protein was significantly associated with resis-
tance to RA and also lower expression of ZNF423 (Figure S3).
An overview of genomic defects of NF1 was obtained by a
comprehensive single-nucleotide polymorphism (SNP) analysis
(Illumina 657K platform) in 20 neuroblastoma cell lines (Fig-
ure 6B). We detected homozygous microdeletions in SJ-NB10
(NB90-9) and SK-N-FI cells, deleting part of NF1 or NF1 and a
neighboring gene (Figures S4A and S4B). The cell line GI-ME-N
showed a 3.6 Mb hemizygous deletion encompassing NF1,
whereas the second NF1 allele had a microdeletion. AMC106
and SK-N-AS cells showed hemizygous deletions of the NF1
region of 3.7 and 5.4 Mb. Five more cell lines (NMB, N206,
SK-N-BE, UHGNP, and SJ-NB8) showed loss of heterozygosityCell 142, 218–encompassing theNF1 region. Only 10/20
cell lines had two apparently normal NF1
alleles.
These results urged us to screen for
mutations of NF1 in the AMC patient
cohort that covers a representative spec-
trum of neuroblastoma and ganglioneur-
oma cases including different disease
stages, ages, and MYCN amplifications.
Sequencing of the full coding region in
cDNA identified two mutations, which
were both confirmed by sequencing of
the genomic exons (Figure 6C). One
neuroblastoma carried a 5 base pair dele-
tion in exon 34 inducing a frameshift.
A ganglioneuroma was detected with a
missense mutation in exon 15, which is
also known from neurofibromatosis type
1 patients (Griffiths et al., 2007). Reanaly-
sis of the clinical records revealed that the
patient in our series was indeed diag-nosed with neurofibromatosis type 1. Sequencing of the exonic
DNA of this tumor revealed that besides the mutated allele,
also a normal NF1 allele was present. However, at the cDNA
level, only expression of the mutant allele was observed,
suggesting epigenetic silencing of the normal NF1 allele (Fig-
ure S4C). Finally, we performed an SNP analysis of 50 neuroblas-
toma patients from the AMC series. This identified one tumor
with a 390 kb heterozygous deletion covering NF1, as well as
two tumors with translocations involving chromosome 17 with
breakpoints in NF1, resulting in gain of distal chromosome 17q
starting in NF1 (Figure 6C). We conclude that NF1 aberrations
are detected in primary neuroblastomas, but at lower frequency
than in neuroblastoma cell lines.
Restoration of RA Responsiveness
RA maintenance therapy has a modest, but significant, benefit
for high-risk neuroblastoma patients. Our results suggest that
tumors with activated RAS signaling, e.g., by NF1 loss/mutation
and low expression of ZNF423, would respond poorly to RA. We229, July 23, 2010 ª2010 Elsevier Inc. 225
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Figure 7. Restoration of RA Responsive-
ness
(A) Constitutively active RAF (BRAFV600E) and MEK
(MEK-DD, MEK1S218D,S222D) recapitulate resis-
tance to RA caused by KRASV12. SH-SY5Y cells
expressing pBabe vector control or the indicated
active alleles of RAS effector pathways were
cultured for 12 and 20 days in the absence or
presence of 1 mM RA and then fixed, stained,
and photographed.
(B) Level of phosphorylated ERK and AKT in the
SH-SY5Y cells described in Figure 7A.
(C) Activation of the RA target gene TGM2 in
SH-SY5Y cells described in Figure 7A. Cells were
grown for 14 days in the absence or presence of
1 mM RA.
(D) MEK inhibition restores RA sensitivity in NF1
knockdown cells. SH-SY5Y cells expressing
shGFP control or shNF1 were grown in the
absence or presence of 1 mM RA for 13 and
18 days. Cells were additionally treated with or
without the MEK inhibitor U0126 at various
concentrations. Cells were then fixed, stained,
and photographed.
(E–G) Inhibition of MEK signaling and re-expres-
sion of ZNF423 and TGM2 inNF1 knockdown cells
treated with MEK inhibitor U0126. SH-SY5Y cells
expressing shGFP control or shNF1 grown in the
presence of 1 mMRA for 9 days and then addition-
ally treated with or without U0126 for 2 days.
Levels of phosphorylated ERK were detected by
western blotting (E). ZNF423 and TGM2 mRNA
expression was determined by qRT-PCR. Error
bars denote SD. **p < 0.001 (t test for comparison
of three biological independent experiments).
See also Figure S5.reasoned that inhibitors of downstream components of RAS
could potentially restore sensitivity to RA in these tumors. To
address this concept, we first dissected the contribution of the
major RAS downstream effector pathways by expressing
respective active alleles. BRAFV600E and MEK-DD conferred
resistance to RA, in contrast to PIK3CAH1047R, RALAQ75L, and
RALBQ72L (Figure 7A). Noteworthy, the activation of AKT by
PIK3CAH1047R was comparable to that by KRASV12 (Figure 7B).
Even expression of highly active myristylated AKT failed to
potently rescue cells from RA-mediated growth arrest. Further,
only KRASV12, BRAFV600E, and MEK-DD blocked RA target
gene activation (Figure 7C). Therefore, the RAF-MEK cascade
is the predominant pathway responsible for resistance to RA
by NF1 loss in neuroblastoma cells.226 Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc.Next, we added increasing concentra-
tions of the MEK inhibitor U0126 with or
without RA to SH-SY5Y cells expressing
either shGFP or shNF1 (Figure 7D).
Addition of U0126 restored sensitivity to
RA in NF1 knockdown cells that were
otherwise resistant. Application of U0126
affected cell growth only moderately in
the absence of RA. Importantly, MEK
inhibition partially restored ZNF423 ex-pression and subsequently RA target gene expression in NF1
knockdown cells and also other NF1low neuroblastoma cell lines
(Figures 7E–7G and Figure S5). Thus, the combination of RA and
a MEK inhibitor might be a valid strategy for the maintenance
therapy of high-risk neuroblastoma, in particular for tumors
with low or mutated NF1.
DISCUSSION
Through an unbiased large-scale RNAi screen in neuroblastoma
cells, we identify here an unexpected role in RA signaling for the
tumor suppressor NF1. The NF1 protein is known to antagonize
activation of RAS proteins, but it has also been implicated in
other pathways such as cAMP/PKA signaling (Tong et al., 2002).
In this study, we provide several lines of evidence that NF1 con-
trols the response to RA in neuroblastoma through the RAS-MEK
signaling cascade. We identify here a mechanistic connection
between NF1-RAS-MEK and RA signaling by showing that
the NF1-RAS-MEK cascade suppresses expression of the
RAR/RXR coactivator ZNF423 (Figures 4A and 4B and Fig-
ure 7B). We have shown recently that ZNF423 is critically
required for the response to RA in neuroblastoma (Huang
et al., 2009). Restoration of ZNF423 expression in NF1low neuro-
blastomas partially restored their responsiveness to RA, under-
scoring the relevance of the regulation of ZNF423 by NF1.
Furthermore, we find that inhibition of the MEK kinase, a down-
stream effector of RAS signaling, with a small-molecule inhibitor
restored ZNF423 expression in NF1 knockdown cells and
restored both RA target gene expression and sensitivity to RA.
These experiments place ZNF423 downstream of the NF1-
RAS-MEK signaling cascade and provide a rationale for the
combination of RA with MEK inhibitors in the clinic to induce
differentiation, apoptosis, and growth arrest in NF1low tumors,
a phenotype seen in over half of primary neuroblastomas.
Other studies have also suggested a role forMAPK signaling in
regulation of responses to RA in different cellular systems (Anto-
nyak et al., 2003; Bruck et al., 2009; Delaune et al., 2008; Gianni
et al., 2006; Kosa et al., 1995; Quinlan et al., 2008; Verheijen
et al., 1999). These data indicate that the effects of MAPK
signaling on RA responses can be heterogeneous. This may be
explained by cell type-specific regulatory mechanisms. Indeed,
RARs can use a multitude of coactivators, some of which are
cell type specific, including ZNF423. Moreover, there is evidence
that short-term responses to MAPK signaling are quite distinct
from the long-term effects we studied here. For example,
p38MAPK activates RAR signaling by phosphorylation of RARa
by MSK1, a p38MAPK-activated kinase, but also inhibits RAR
signaling later by phosphorylation and degradation of the
RARa coactivator SRC3 (Gianni et al., 2006). However, a role
for the p38MAPK pathway in RA-mediated long-term growth
arrest in neuroblastoma has not been established.
Given that RAplays a central role in neuronal differentiation and
that Rara-knockout mice exhibit neural crest defects (McCaffery
et al., 2003), we reasoned that NF1 expression could potentially
impact the clinical course of neuroblastoma and even act as
a tumor suppressor in human neuroblastoma. In three indepen-
dent gene expression datasets of 316 neuroblastoma patients in
total, we found that low expression of NF1 (NF1low), in particular
in combination with ZNF423low, correlated with a very poor
outcome (Figure 5). Tumors having both NF1low and ZNF423low
constitute a clinically significant subgroup. In contrast, high
expression of both was associated with the best prognosis.
NF1low tumors were significantly enriched in the ZNF423low
subgroup, suggesting that hyperactive RAS-MEK signaling also
contributes tosuppressionofZNF423 in primaryneuroblastomas.
Proteasomal degradation of NF1, as observed in glioblastoma,
could also account for active RAS signaling and suppression of
ZNF423 (McGillicuddy et al., 2009). As RAS mutations occur
rarely if ever in primary neuroblastoma, other negative or positive
regulators of RAS signaling could be involved as well. In addition,
control of ZNF423 level by independent signaling pathways could
antagonize or synergize with RAS signaling.Germline mutations in NF1 are linked to neurofibromatosis
type 1, and somatic mutations and deletions are frequent in glio-
blastoma (Messiaen et al., 2000; TCGA_Network, 2008). The
data demonstrating the poor prognosis of patients with NF1low
expression sparked our interest in asking if NF1 could also be
lost by mutation in neuroblastoma. We found two sequence
mutations and three genomic aberrations (microdeletion, 17q
duplication) in the NF1 gene out of 83 analyzed tumors. Based
on a few incidental case reports, a predisposition of neurofibro-
matosis type 1 patients for neuroblastoma has been proposed
(Martinsson et al., 1997; Origone et al., 2003). Indeed, the iden-
tified H553R missense mutation in NF1 proved to be a neurofi-
bromatosis type 1-associated germline mutation. The germline
status is unknown for the other patient having a five base pair
deletion in NF1. Remarkably, this patient was diagnosed as
stage 2 disease, which in general has an excellent prognosis.
Nevertheless, this patient was the only one of the 23 stage 1/2
neuroblastoma patients in the AMC cohort that died of disease.
The mutation rate of NF1 in neuroblastoma was lower than
reported for glioblastoma. It is reasonable to expect fewer muta-
tions in an embryonal tumor-like neuroblastoma than in a highly
genomic unstable and largely p53-deficient adulthood malig-
nancy. In addition, low- and intermediate-risk neuroblastomas
(50% of the AMC cohort) have a very good disease outcome,
and because low expression of NF1 correlated with poor
outcome, we speculate that NF1 mutations are more prevalent
in high-risk disease. However, larger cohorts will be required to
investigate this hypothesis.
In conclusion, we found genomic aberrations of the NF1 gene
in 6% (5/83) of primary neuroblastomas, supporting a direct role
for NF1 in the pathogenesis of the disease, at least in a subset of
cases. Noteworthy, activating mutations in the protein-tyrosine
phosphatase PTPN11 (SHP2), an enhancer of RAS signaling,
have been previously described in 3.4% (3/89) of neuroblas-
tomas (Bentires-Alj et al., 2004). Dominant mutations in
PTPN11 cause the developmental disorder Noonan syndrome
and possibly predispose to neuroblastoma (Cotton andWilliams,
1995; Tartaglia et al., 2001). Together with our functional, muta-
tional, and survival studies onNF1, these results further substan-
tiate a role for aberrant RAS signaling in the development of
neuroblastoma, even though RAS mutations are rarely, if ever,
found in this type of cancer (Moley et al., 1991).
Our data predict that low levels of ZNF423 and NF1 will be
associated with poor response to RA-based therapies in the
clinic. To begin to address this, we asked if we could observe
a correlation between ZNF423 levels and RA responsiveness in
a panel of 26 neuroblastoma cell lines. We reasoned that loss
of NF1 causes suppression of ZNF423 expression (Figures 4A
and 4B) and hence that ZNF423 levels would also report NF1
status in neuroblastoma cell lines. Indeed, we found that high
expression of ZNF423 significantly correlated with sensitivity to
RA (Figure 4E). The range of ZNF423 expression in the cell line
panel corresponds well to the 3- to 4-fold repression of
ZNF423 caused by loss of NF1.
RA is used as a maintenance therapy with some success for
high-risk neuroblastoma, and levels of NF1 and/or ZNF423 may
well account for at least a fraction of nonresponders in the clinic.
Our finding that MEK inhibitors can restore responsiveness toCell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc. 227
RA in vitro inNF1low cells suggests apotential strategy to improve
the therapeutic efficacy of retinoids in the treatment of neuroblas-
toma. As highly selective MEK inhibitors are currently evaluated
in clinical trials, their combination with RA could be an attractive
therapeutic approach.
Most, if not all, established predictive biomarkers for targeted
therapies affect the target itself or key downstream components
of the signaling pathway targeted by the drug. For example,
KRAS mutations confer resistance to epidermal growth factor
receptor (EGFR)-targeted therapy in colon cancer, and PIK3CA
mutations or lack of PTEN expression correlate with poor
response to trastuzumab in HER2-positive breast cancer (Berns
et al., 2007; Karapetis et al., 2008). Our results reveal a paradigm
for predictive biomarkers by demonstrating that aberrant activity
of lateral signaling pathways can determine the response to a
targeted therapeutic without mutations in any of the core com-
ponents of the pathway itself. Our data highlight the importance
of mapping crosstalk between signaling pathways to predict
responses to targeted therapies in cancer. Unbiased genetic
screens are powerful tools to identify these genetic interactions,
and the present case even suggests a therapeutic strategy to
restore drug response in resistant patients.EXPERIMENTAL PROCEDURES
shRNA Barcode Screen
The NKI shRNA library and the barcode screen are as described (Berns et al.,
2004; Brummelkamp et al., 2006). Additional details can be found at http://
screeninc.nki.nl/.
Cell Proliferation Assays
Single-cell suspensions were seeded into 6-well plates (1–2 3 104 cells/well)
and cultured both in the absence and presence of RA. At the endpoints of
colony formation assays, cells were fixed, stained with crystal violet, and
photographed. All knockdown and overexpression experiments were done
by retroviral infection. For the experiments to measure RA responsiveness in
the panel of 26 neuroblastoma cell lines, each line was subjected to long-
term colony formation assays in triplicates in the absence or presence of
100 nM RA. Treated and untreated dishes of each cell line were harvested
at the same time. Crystal violet stain was then extracted using 10% acetic
acid and quantified at optical density (OD) 590 nm. The growth curves were
performed according to the standard 3T3 protocol. All relevant assays were
performed independently at least three times.
Patient Samples
For all studies presented, the expression data were obtained using Affymetrix
microarray analyses on the untreated primary tumor samples at the time of
diagnosis. The patient samples for both cohorts and the definition of an event
(progression-free survival) for both cohorts are as described (Asgharzadeh
et al., 2006; Huang et al., 2009). Written informed consent was obtained
from patients’ parents or guardians in accordance with institutional review
board policies and procedures for research dealing with tumor specimen
and clinical information. The institutional review board at Childrens Hospital
Los Angeles (CHLA) and the medical-ethics committee of the Academic
Medical Center (AMC) in Amsterdam approved the study.
Statistical Analysis
To determine the optimal value to set as a cut-off for NF1 expression in the
AMC cohort, kaplan scanning was used as described for the cut-off for
ZNF423 (Huang et al., 2009). The cut-off value was validated using a second
independent set of 102 CHLA patients (Asgharzadeh et al., 2006). See
Extended Experimental Procedures for more details. Progression-free survival228 Cell 142, 218–229, July 23, 2010 ª2010 Elsevier Inc.was measured for all outcome analysis presented in this study using the same
NF1 and/or ZNF423 cut-off values.
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